Agios Stock Analysis

AGIO -  USA Stock  

USD 48.09  1.75  3.51%

Agios Pharmaceuticals price slide over the last few months could raise concerns from institutional investors as the firm it trading at a share price of 48.09 on 1,220,000 in volume. The company directors and management were not very successful in positioning the firm resources to exploit market volatility in July. However, diversifying your holdings with Agios Pharmaceuticals or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 2.22. The current volatility is consistent with the ongoing market swings in July 2021 as well as with Agios Pharmaceuticals unsystematic, company-specific events.
Please continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Agios Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Agios Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Agios Stock analysis module also helps to analyze the Agios Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Agios Stock Analysis Notes

About 108.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.52. Some equities with similar Price to Book (P/B) outperform the market in the long run. Agios Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 0.05. The entity recorded earning per share (EPS) of 22.93. The firm had not issued any dividends in recent years. Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts. Agios Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 562 people. For more info on Agios Pharmaceuticals please contact David Schenkein at 617 649-8600 or go to www.agios.com.

Agios Pharmaceuticals Quarterly Cost of Revenue

0.0Share

Agios Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Agios Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Agios Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Agios Pharmaceuticals generates negative expected return over the last 90 days
The company reported the previous year's revenue of 203.2 M. Net Loss for the year was (334.15 M) with loss before overhead, payroll, taxes, and interest of (167.08 M).
Agios Pharmaceuticals currently holds about 2.34 B in cash with (306.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 33.4.
Agios Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Latest headline from www.equities.com: Agios Pharmaceuticals Inc gains 0.50 percent for July 19 - Equities.com

Agios Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Agios Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Agios Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report29th of July 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Agios Largest EPS Surprises

Earnings surprises can significantly impact Agios Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2014-03-06
2013-12-31-0.34-0.4-0.0617 
2014-08-07
2014-06-30-0.4-0.54-0.1435 
2016-08-04
2016-06-30-1.3035-1.47-0.166512 
View All Earnings Estimates

Agios Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Agios Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Agios Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Agios Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
21st of June 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
11th of June 2021
Financial Statements and Exhibits. Other Events
View
21st of May 2021
Submission of Matters to a Vote of Security Holders
View
29th of April 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
6th of April 2021
Financial Statements and Exhibits
View
5th of April 2021
Unclassified Corporate Event
View
2nd of April 2021
Financial Statements and Exhibits. Other Events. Completion of Acquisition or Disposition of Assets. Entry into a Material Definitive Agreement
View
25th of March 2021
Financial Statements and Exhibits. Other Events. Submission of Matters to a Vote of Security Holders
View

Agios Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Agios Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Agios Pharmaceuticals backward and forwards among themselves. Agios Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Agios Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Eagle Health Investments LpCommon Shares235.5 K13 M
Alliancebernstein LpCommon Shares74 K4.1 M
State Of New Jersey Common Pension Fund DCommon Shares45 K2.5 M
Strs OhioCommon Shares26.6 K1.5 M
Zurcher Kantonalbank Zurich CantonalbankCommon Shares6.7 K371 K
Sco IncCommon SharesK330 K
North Star Asset Management IncCommon Shares5.6 K309 K
Note, although Agios Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Agios Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 3.08 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Agios Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Agios Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Agios Profitablity

Agios Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Agios Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Agios Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Agios Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Agios Pharmaceuticals' profitability requires more research than a typical breakdown of Agios Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 781.12 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of (157.65) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -1.58.
Last ReportedProjected for 2021
Return on Investment(60.70) (65.50) 
Return on Average Assets(0.37) (0.40) 
Return on Average Equity(0.64) (0.69) 
Return on Invested Capital(0.37) (0.40) 
Return on Sales(1.61) (1.74) 

Management Efficiency

The entity has return on total asset (ROA) of (12.18) % which means that it has lost $12.18 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (22.87) %, meaning that it created substantial loss on money invested by shareholders. Agios Pharmaceuticals management efficiency ratios could be used to measure how well agios pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to slide to -65.5. The value of Return on Average Assets is estimated to slide to -0.4. Agios Pharmaceuticals Tax Assets are quite stable at the moment as compared to the past year. The company's current value of Tax Assets is estimated at 4.41 Million. Revenue to Assets is expected to rise to 0.26 this year, although the value of Total Assets will most likely fall to about 754.6 M.
Last ReportedProjected for 2021
Book Value per Share 5.79  5.21 
Enterprise Value over EBIT(10.00) (10.79) 
Enterprise Value over EBITDA(10.58) (11.41) 
Price to Book Value 7.51  6.59 
Tangible Assets Book Value per Share 12.36  15.55 
Enterprise Value3.3 B3.1 B
Tangible Asset Value853 M754.6 M

Technical Drivers

As of the 31st of July, Agios Pharmaceuticals shows the mean deviation of 1.61, and Risk Adjusted Performance of (0.06). Agios Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Agios Pharmaceuticals, which can be compared to its rivals. Please confirm Agios Pharmaceuticals variance, as well as the relationship between the maximum drawdown and semi variance to decide if Agios Pharmaceuticals is priced correctly, providing market reflects its regular price of 48.09 per share. Given that Agios Pharmaceuticals has jensen alpha of (0.21), we suggest you to validate Agios Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Agios Pharmaceuticals Price Movement Analysis

The output start index for this execution was fifty-nine with a total number of output elements of two. The Moving Average is predictive technique used to analyze Agios Pharmaceuticals price data points by creating a series of averages of different subsets of Agios Pharmaceuticals entire price series. View also all equity analysis or get more info about all moving average overlap studies indicator.

Agios Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Agios Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Agios Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Agios Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Carman Alenson over a month ago via Macroaxis 
Exercise or conversion by Carman Alenson of 1777 shares of Agios Pharmaceuticals subject to Rule 16b-3
Christopher Bowden over a month ago via Macroaxis 
Exercise or conversion by Christopher Bowden of 46608 shares of Agios Pharmaceuticals subject to Rule 16b-3
Christopher Bowden over a month ago via Macroaxis 
Exercise or conversion by Christopher Bowden of 2502 shares of Agios Pharmaceuticals subject to Rule 16b-3
Christopher Bowden over a month ago via Macroaxis 
Exercise or conversion by Christopher Bowden of 6675 shares of Agios Pharmaceuticals subject to Rule 16b-3
David Scadden over a month ago via Macroaxis 
Exercise or conversion by David Scadden of 1686 shares of Agios Pharmaceuticals subject to Rule 16b-3
David Scadden over two months ago via Macroaxis 
Acquisition by David Scadden of 8888 shares of Agios Pharmaceuticals subject to Rule 16b-3
Darrin Miles over two months ago via Macroaxis 
Sale by Darrin Miles of 3462 shares of Agios Pharmaceuticals
Christopher Bowden over three months ago via Macroaxis 
Exercise or conversion by Christopher Bowden of 1888 shares of Agios Pharmaceuticals subject to Rule 16b-3
Carman Alenson over three months ago via Macroaxis 
Sale by Carman Alenson of 991 shares of Agios Pharmaceuticals
Car Bruce over three months ago via Macroaxis 
Exercise or conversion by Car Bruce of 3437 shares of Agios Pharmaceuticals subject to Rule 16b-3
Darrin Miles over three months ago via Macroaxis 
Sale by Darrin Miles of 500 shares of Agios Pharmaceuticals
Darrin Miles over three months ago via Macroaxis 
Exercise or conversion by Darrin Miles of 725 shares of Agios Pharmaceuticals subject to Rule 16b-3

Agios Pharmaceuticals Predictive Daily Indicators

Agios Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Agios Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Agios Pharmaceuticals Forecast Models

Agios Pharmaceuticals time-series forecasting models is one of many Agios Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Agios Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Agios Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Agios Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Agios shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Agios Pharmaceuticals. By using and applying Agios Stock analysis, traders can create a robust methodology for identifying Agios entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin(95.25) (102.77) 
EBITDA Margin(1.52) (1.64) 
Gross Margin 0.99  0.94 
Profit Margin(1.61) (1.74) 
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts. Agios Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 562 people.

Current Agios Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Agios analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Agios analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
63.29Buy7Odds
Agios Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Agios analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Agios stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Agios Pharmaceuticals, talking to its executives and customers, or listening to Agios conference calls.
Agios Analyst Advice Details

Agios Stock Analysis Indicators

Agios Pharmaceuticals stock analysis indicators help investors evaluate how Agios Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Agios Pharmaceuticals shares will generate the highest return on investment. By understating and applying Agios Pharmaceuticals stock analysis, traders can identify Agios Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio24.20
Fifty Two Week Low32.47
Shares Short Prior Month5.11M
Average Daily Volume Last 10 Day1.17M
Average Daily Volume In Three Month734.84k
Shares Percent Shares Out7.23%
Gross Margins-83.36%
Short Percent Of Float11.61%
Forward Price Earnings-7.80
Float Shares69.21M
Fifty Two Week High62.16
Enterprise Value To Ebitda-5.59
Fifty Day Average56.75
Two Hundred Day Average53.33
Enterprise Value To Revenue8.54
Please continue to Trending Equities. Note that the Agios Pharmaceuticals information on this page should be used as a complementary analysis to other Agios Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Agios Stock analysis

When running Agios Pharmaceuticals price analysis, check to measure Agios Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Agios Pharmaceuticals is operating at the current time. Most of Agios Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Agios Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Agios Pharmaceuticals' price. Additionally, you may evaluate how the addition of Agios Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
The market value of Agios Pharmaceuticals is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Agios Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharmaceuticals' market value can be influenced by many factors that don't directly affect Agios Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Agios Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.